ClinicalTrials.gg
CompletedNCT07819955Updated Sep 15, 2026

Comparison of the Pain and Functional Improvement of Combined Extracorporeal Shockwave Therapy With or Without Intra-articular Hyaluronic Acid and Platelet-rich Plasma Injection on Advanced Osteoarthritis of the Knees.

An interventional study of Extracorporeal Shock Wave Therapy and Normal Saline in Osteoarthritis (OA), sponsored by Chang Gung Memorial Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Aug 2023, registered Sep 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing Hyaluronic Acid in Osteoarthritis — 2 open to participants now, 2 under way, none of them phase 3. Hyaluronic Acid · Osteoarthritis.

Enrollment
10th of 15
48 · median 60
Started
2023
with 1 other
No phase
7 of 16
2 open now
Registered
16th of 16
by date
Lead sponsor
1 of 16
Chang Gung Memorial Hospital

Among the 16 studies testing Hyaluronic Acid in Osteoarthritis, this one is the 10th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2023, is one of 7 with no phase, and was the 16th registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

2 of the 16 studies testing Hyaluronic Acid in Osteoarthritis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Hyaluronic Acid

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing Hyaluronic Acid in Osteoarthritis, or all of them as a file.
02

Study summary

This was a single group, double-blind, randomized clinical trial that enrolled 48 patients with Kellgren-Lawrence grade II to IV osteoarthritis of the knee. Patients were randomly assigned to three groups: Saline + ESWT (S+E group), High Platelet-Rich Plasma (PRP + ESWT (P+E group), and Hyaluronic Acid + ESWT (HA + ESWT (H+E group). All patients were followed for one year. Assessments included the Visual Analogue Scale (VAS), serum enzyme-linked immunosorbent assay (ELISA), knee X-ray and ultrasound examinations, and functional scores (WOMAC, KOOS, and IKDC).

Read the detailed description

This is a double-blind trial. The first year's work primarily involves patient enrollment, treatment, and evaluation. We anticipate enrollment will take one year; therefore, patients meeting the inclusion criteria will be gradually enrolled during the first year. Upon enrollment, each patient will undergo blood tests, functional assessments, X-rays, and ultrasound examinations as pre-treatment data. After treatment (depending on their assigned group), functional assessments will be performed every three months, and X-rays and ultrasound examinations will be conducted six months later. The entire treatment period for each patient is one year (6 months of treatment + 6 months of follow-up).

Extracorporeal shock wave therapy (ESWT) is a single high-amplitude sound wave generated by a high-voltage capacitor spark discharge explosion and then focused on the area we want to treat through an elliptical reflector.

Hyaluronic acid is a long-chain polymer composed of disaccharide molecules of D-glucuronic acid and N-acetylglucosamine. It is a major component of the extracellular matrix and is widely present in human body fluids and tissues, including the vitreous humor of the eye and synovial fluid of joints. During osteoarthritis, the concentration and molecular weight of endogenous hyaluronic acid decrease significantly, leading to a decline in its effectiveness in lubricating joints and dispersing intra-articular pressure . Exogenous hyaluronic acid supplementation is effective in anti-inflammatory effects, stimulating the regeneration of endogenous hyaluronic acid, and relieving pain. Current literature confirms that intra-articular injection of hyaluronic acid can be considered as a treatment option to relieve osteoarthritis when other conservative treatments are ineffective .

On the other hand, platelet-rich plasma (PRP) is an emerging treatment option for osteoarthritis of the knee (9). PRP is plasma rich in platelets that can be separated from the patient's own blood using centrifugation. Platelets are organelles in the human body that readily obtain growth factors; therefore, high-concentration platelet plasma also contains many growth factors, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and transforming growth factor (TGF). These high concentrations of growth factors can be used to achieve tissue repair and regeneration. Previous literature has also confirmed that PRP can effectively reduce pain and improve function in patients with osteoarthritis. However, the effects of these two treatment methods on cartilage tissue improvement remain inconclusive.

03

Conditions studied

  • Osteoarthritis (OA)

Browse trials for

Keywords

  • Osteoarthritis
  • Hyaluronic Acid
  • Platelet-Rich Plasma
  • Extracorporeal Shock Wave Therapy
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 20 years and older with phase II, III, or IV osteoarthritis of the knee. The phase of osteoarthritis of the knee is defined according to the Kellgren-Lawrence classification; phase II: Only slight narrowing of the joint cavity, with visible bone spurs.

phase III: Numerous bone spurs, significant narrowing of the joint cavity, and subchondral cysts visible in the subchondral bone.

phase IV: Larger and more prominent bone spurs, severe narrowing of the joint cavity, sclerosis of the subchondral bone, and even joint deformities.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding women.
  2. Patients with arrhythmia or those with pacemakers.
  3. Patients with tumors.
  4. Individuals with coagulation disorders.
  5. Patients with chronic renal failure ( \< 60).
  6. Patients with known allergies to hyaluronic acid, or those with infections or skin diseases.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
48 participants (actual)

Study arms

  • Placebo comparator
    ESWT+normal saline

    Each group received ESWT treatment and an injection of Saline as a placebo to prevent participants from knowing they were in the control group.

    Device: Extracorporeal Shock Wave Therapy · Drug: Normal Saline

  • Experimental
    ESWT+Hyaluronic Acid(HA)

    This group of patients will receive ESWT and HA injections.

    Device: Extracorporeal Shock Wave Therapy · Drug: Hyaluronic Acid (HA)

  • Experimental
    ESWT+Platelet-Rich Plasma(PRP)

    This group of patients will receive ESWT and PRP injections.

    Device: Extracorporeal Shock Wave Therapy · Biological: Platelet-Rich Plasma

Interventions

  • DeviceExtracorporeal Shock Wave Therapy

    Extracorporeal Shock Wave Therapy (ESWT) is a non-invasive, injection-free, and radiation-free treatment method commonly used to treat musculoskeletal disorders. Compared to conventional instrument-based treatments, it can reach deeper tissues. Shock waves can cause microscopic damage to injured or poorly healed tissues, promoting tissue repair, angiogenesis, and pain relief. Using a Storz Medical shockwave therapy machine at an energy of 0.25 mJ/mm², 4000 shocks were administered each time, followed by three treatments at two-week intervals.

  • DrugNormal Saline

    Physiological saline solution is a mixture of sodium chloride (salt) and water, with a concentration of 0.9%, and its osmotic pressure is equal to that of human body fluids. Because sterile physiological saline solution has a simple composition and its osmotic pressure is similar to that of the human body and it has no pharmacological activity, it is often used as a sham treatment control group.

  • Hyaluronic acid (also known as hyaluronic acid) is a biological polysaccharide with high water absorption and viscoelasticity. It is a component of the articular cartilage matrix and one of the main components of joint lubricating fluid. Hyaluronic acid in the joint cavity can help joints move smoothly, cushion impacts, and reduce wear and tear between articular cartilage.

  • PRP therapy mainly involves drawing the patient's own blood, centrifuging it at high speed through a special extraction tube to separate platelets, and then injecting the concentrated platelets into the joint cavity. Utilizing the repair and regeneration capabilities of the growth factors abundant in the platelet vesicles, it repairs the worn-out meniscus cartilage, promotes tissue regeneration, and relieves the pain of degenerative knee osteoarthritis.

06

What researchers measure

Primary outcomes

  1. VAS(Visual Analogue Scale)

    VAS(Visual Analogue Scale):Ask the patient to mark the degree of their pain on a 10 cm line, from "no pain" on the far left to "unbearable pain" on the far right. The "Numerical Rating Scale" uses a numerical concept of 0-10 points to express the degree of pain, from no pain (0 points) to very painful (10 points).

    Time frame: Functional assessments were performed at months 0, 3, 6, 9, and 12 of the treatment course.

  2. WOMAC(Western Ontario and McMaster Universities Arthritis Index)

    WOMAC is a standardized questionnaire specifically designed to assess the symptoms and functional status of osteoarthritis (degenerative joint disease) of the knee and hip. WOMAC contains 24 items, divided into three categories. Pain (5 items): Assess the degree of pain when walking, climbing stairs, lying down, sitting, or standing. Score range: 0 to 20. Stiffness (2 items): Assess the feeling of stiffness in the joints upon waking in the morning and after resting during the day. Score range: 0 to 8. Physical Function (17 items): Assess the difficulty of performing daily activities such as climbing stairs, getting up, bending over, walking, putting on socks, and doing housework. Score range: 0 to 68.The Likert scale was used for scoring:0 for none, 1 for mild, 2 for moderate, 3 for severe, and 4 for very severe. Total score: The sum of the three scores ranges from 0 to 96. A higher score indicates more severe arthritis symptoms and greater functional impairment.

    Time frame: Functional assessments were performed at months 0, 3, 6, 9, and 12 of the treatment course.

  3. KOOS scale (Knee Injury and Osteoarthritis Outcome Score)

    The KOOS scaleis a standardized questionnaire used to assess the subjective symptoms and quality of life of patients with knee injuries and osteoarthritis. KOOS contains 42 items, independently assessing the following five subscales: 1. Pain: Assessing the frequency and severity of knee pain. 2. Other symptoms: Including swelling, clicking, limited extension or flexion, etc. 3. Daily Living Functions : Ease of performing everyday actions such as going down stairs, sitting down, and putting on socks. 4. Sport/Rec: Performance in activities such as running, jumping, kneeling, or squatting.5. Quality of Life : The psychological impact and distress caused by knee condition on daily life. Scoring Method: Each item is scored on a Likert scale from 0 to 4. Score Range: Each of the five categories is calculated independently and converted to a percentage scale from 0 to 100. Score Meaning: 0 represents the worst knee condition, extremely severe; 100 represents no symptoms and excellent knee

    Time frame: Functional assessments were performed at months 0, 3, 6, 9, and 12 of the treatment course.

  4. IKDC (International Knee Documentation Committee Subjective Knee Form)

    IKDC is suitable for patients with various knee joint conditions (such as ligament injuries, meniscus tears, cartilage problems, or osteoarthritis), and is particularly commonly used for sports injuries and post-operative follow-up. It covers three main categories: symptoms (pain, stiffness, swelling, locking, or weakness. Assess three core symptom categories: assess frequency and severity of pain, stiffness, swelling, joint locking, or knee displacement. Assess sports and activities: assess limitations in daily activities (such as climbing stairs, standing up from a chair, squatting) and during movement or jumping. Assess current overall knee function: the patient's rating of their current knee condition compared to before the injury. Scoring and Interpretation: Score range: 0 to 100. Meaning: Higher scores indicate better function and fewer symptoms; 100 points indicates no symptoms and no limitations in daily life or sports.

    Time frame: Functional assessments were performed at months 0, 3, 6, 9, and 12 of the treatment course.

Secondary outcomes

  1. Enzyme-Linked Immunosorbent Assay

    The serum levels of inflammatory factors cytokine IL-6, metabolic inflammatory factor Leptin, cartilage factor COMP (cartilage oligometric protein), osteoinhibitory protein DKK-1 (Dickkopf-1), and cartilage-degrading enzyme MMP-3 (Matrix Metalloproteinase-3) were analyzed.

    Time frame: Functional assessments were performed at months 0, 6, and 12 of the treatment course.

Other outcomes

  1. Ultrasound Assessment: Joint Effusion

    Measurement of joint effusion in the knee joint using ultrasound examination.Unit of Measure:millimeter (mm)

    Time frame: Functional assessments are performed at months 0, 6, and 12 of treatment.

  2. Ultrasound Assessment: Medial Meniscus (MM) Extrusions Width at Full Extension

    Measurement of medial meniscus extrusion width at full extension using ultrasound examination.Unit of Measure: millimeter(mm)

    Time frame: Functional assessments were performed at months 0, 6, and 12 of the treatment course.

  3. Ultrasound Assessment: Medial Meniscus (MM) Extrusion Width at Standing Weight-Bearing

    Measurement of medial meniscus extrusion width during standing weight-bearing using ultrasound examination.Unit of Measure: millimeter(mm)

    Time frame: Functional assessments were performed at months 0, 6, and 12 of the treatment course.

  4. Ultrasound Assessment: Medial Collateral Ligament (MCL) Thickness at Full Extension

    Measurement of medial collateral ligament thickness at full extension using ultrasound examination.Unit of Measure: millimeter(mm)

    Time frame: Functional assessments were performed at months 0, 6, and 12 of the treatment course.

  5. Ultrasound Assessment: Medial Collateral Ligament (MCL) Thickness at Standing Weight-Bearing

    Measurement of medial collateral ligament thickness during standing weight-bearing using ultrasound examination.Unit of Measure: millimeter(mm)

    Time frame: Functional assessments were performed at months 0, 6, and 12 of the treatment course.

  6. Ultrasound Assessment: Doppler Signal at Medial Meniscus (MM) Body

    Assessment of vascularization and inflammation via Doppler ultrasound signal at the medial meniscus body.Unit of Measure: ( Semi-quantitative scale, 0-3)

    Time frame: Functional assessments were performed at months 0, 6, and 12 of the treatment course.

07

Study locations

1 site
  • Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung City, Kaohsiung 833401, Taiwan
08

References and documents

Individual participant data

Plan to share: No — Patient privacy and Institutional Review Board regulations

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Jun 2025, 22 months.

Of 576 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's 22 months is below that.

Counting every sponsor, half of 711 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2026
First posted
Sep 15, 2026
StartActual
Aug 4, 2023
Primary completionActual
Jun 27, 2025
CompletionActual
Jun 27, 2025
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07819955
Responsible party
Sponsor
First posted
Sep 15, 2026
Start date
Aug 4, 2023
Primary completion
Jun 27, 2025
Completion
Jun 27, 2025
Last update
Sep 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Hyaluronic Acid · Platelet rich plasma

Start the discussion